Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
Authors: Pitisuttithum Punnee , Luvira Viravarn , Lawpoolsri Saranath , Muangnoicharoen Sant , Kamolratanakul Supitcha , Sivakorn Chaisith , Narakorn Piengthong , Surichan Somchaiya , Prangpratanporn Sumalee , Puksuriwong Suttida , Lamola Steven , Mercer Laina D , Raghunandan Rama , Sun Weina , Liu Yonghong , Carreño Juan Manuel , Scharf Rami , Phumratanaprapin Weerapong , Amanat Fatima , Gagnon Luc , Hsieh Ching-Lin , Kaweepornpoj Ruangchai , Khan Sarwat , Lal Manjari , McCroskery Stephen , McLellan Jason , Mena Ignacio , Meseck Marcia , Phonrat Benjaluck , Sabmee Yupa , Singchareon Ratsamikorn , Slamanig Stefan , Suthepakul Nava , Tcheou Johnstone , Thantamnu Narumon , Theerasurakarn Sompone , Tran Steven , Vilasmongkolchai Thanakrit , White Jessica A , Garcia-Sastre Adolfo , Palese Peter , Krammer Florian , Poopipatpol Kittisak , Wirachwong Ponthip , Hjorth Richard , Innis Bruce L 
Published: September 2021

Background

Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It’s being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand.

Methods

This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 µg±CpG1018 (a toll-like receptor 9 agonist), 3 µg±CpG1018, 10 µg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov (NCT04764422).

Findings

Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5·7% to 17·1% among vaccine groups and was 2·9% in controls; there was no vaccine-related serious adverse event. The 10 µg formulation’s immunogenicity ranked best, followed by 3 µg+CpG1018, 3 µg, 1 µg+CpG1018, and 1 µg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) to 474·35 IU/mL (10 µg, 95% CI 320·90-701·19), with 93·9% to 100% of vaccine groups attaining a ≥4-fold increase over baseline.

Interpretation

NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 µg and 3 µg+CpG1018 formulations advanced to phase 2.

Funding

National Vaccine Institute (Thailand), National Research Council (Thailand), Bill & Melinda Gates Foundation, National Institutes of Health (USA)